Targeted Therapies Changed Lung Cancer Care
Personalized genomic testing is helping patients manage advanced disease and improve outcomes.
Updated on Sept. 27, 2026 in Cancer
Live Poll
Do you trust that insurance companies will cover new, personalized medical treatments when you need them?
Since receiving a Stage IV lung cancer diagnosis in May 2024, medical professor Bryant Lin has utilized targeted drug therapies to manage his condition. This approach reflects a broader shift toward personalized medicine in oncology.
Why it matters
Lung cancer treatment now relies on targeted therapies because the disease genetics are complex and diverse. Currently, fewer than half of U.S. patients receive the necessary genetic testing to identify these specific mutations before treatment begins.
National survival data from 2015 to 2021 shows a 30% five-year survival rate for all lung cancer stages, compared to 67% for early localized cases. The efficacy of personalized approaches continues to evolve as researchers study new genomic testing and vaccine strategies.
The players
Bryant Lin
A medical professor and founder of the Stanford Center for Asian Health Research and Education who was diagnosed with Stage IV lung cancer in May 2024.
The details
Doctors use comprehensive genomic testing to identify the specific mutations driving abnormal cell growth in a patient. Targeted medicines then focus attacks on these specific mutated cells to minimize collateral damage to healthy tissue. This precision approach allows clinicians to tailor treatment plans to the unique biological profile of an individual's tumor.
Timeline
2015 to 2021 data provided a benchmark for early localized cancer survival rates.
The FDA approved Tagrisso in combination with chemotherapy in February 2024.
Bryant Lin received his Stage IV lung cancer diagnosis in May 2024.
The FDA approved the drug Rasonque for pancreatic cancer in August 2026.
Health Landscape
This development follows a pattern set by the historical shift from general chemotherapy to targeted oncology. It underscores the ongoing transition toward personalized molecular profiling as the new standard for managing advanced malignancies.
Given that fewer than half of U.S. patients receive genetic testing before treatment, it is worth discussing the availability of genomic profiling with your doctor. Understanding your specific mutation status is a critical step in exploring whether targeted therapies are an option for your care.
The takeaway
Targeted therapies represent a major advance in oncology by focusing treatment on the specific genetic drivers of cancer. Patients should ask their care team if comprehensive genomic testing has been performed to ensure the most precise treatment plan is in place.
Further reading
For more information on the latest approaches to personalized treatment, visit Cancer.
Source note: This article includes information reported by WVIA Public Media.
Live Poll
Do you trust that insurance companies will cover new, personalized medical treatments when you need them?
